Jim Cramer could only explain the decline of the averages on Friday as a repercussion of being in the heart of liquidation season.
Liquidation season occurs when clients of poorly performing hedge funds ask for their money back. It tends to occur at the end of a quarter or year. In response, hedge funds must sell stocks in the open market to raise the money that needs to be returned to investors.
That means if a hedge fund performed poorly this year; it is probably flooded with liquidation requests right now. In fact, there have been more failed hedge funds this year than any time since 2008.
"Just be careful when you try to bottom fish, knowing that the bottom could always be a false bottom, a trapdoor, so to speak, that makes you overconfident versus the miserable moment we seem to be in," Cramer said.
With this in mind, Cramer shared the events and stocks he will be watching next week:
Monday: "Star Wars"
This could be a great opportunity to get into Disney for the long term. The stock was downgraded by an analyst with a recommendation to sell at a $90 price target. However, Cramer thinks "Star Wars" is worth a lot to the company and could translate into sequels, merchandise and theme park business.
On a brutal market day like Friday, Cramer thinks it is important to remember that picking individual stocks still matters, even if it doesn't always feel that way.
This is why Cramer decided to take a closer look at two peculiar pieces of research that surfaced on Wall Street in two large-name stocks. On Dec. 1, Morgan Stanley upgraded British drug company AstraZeneca to overweight from underweight, and Bank of America Merrill Lynch downgraded large engine maker Cummins to underperform from buy.
Why was this strange?
Cramer found these actions unusual because typically analysts will only upgrade or downgrade a stock by one notch at a time. So, if it has a buy rating, they will take it down to a neutral, and then later maybe downgrade it again to a sell.
"You know that I never take this sell-side research as gospel, and you shouldn't either. But following these Wall Street analysts can be an important part of your homework," the "Mad Money" host said.
It was also confirmed on Friday morning that biotech company ISIS Pharmaceuticals is finally changing its name to Ionis Pharmaceuticals to avoid confusion with the other ISIS — as in the so-called Islamic State for Iraq and Syria.
"I think this is a case where a biotech company by any other name would smell just as sweet," Cramer said.
Ionis has pioneered antisense technology by developing drugs that target the RNA in cells, which is close to the biological equivalent of middle management. DNA gives orders, and RNA communicates those orders to the rest of the cells.
To learn more about the decision to change its name, Cramer spoke with Ionis Pharma's chairman and CEO, Dr. Stanley Crooke.
"From my perspective, changing the name rids us of a distraction at a time that is tremendously exciting," Crooke said.
Right now the market seems automated to Cramer. Every time the price of crude oil drops, the also plunges. Some think that computer programs have been correlated to automatically unleash selling in the S&P every time crude goes down.
Why would the stock market run better on Amazon?
"Because it would become accessible to everyone," the "Mad Money" host said.
Cramer envisioned a system where an investor could buy a put option on oil, using Amazon Prime of course, for commission free trading and a pop up would appear that said "If you dislike oil here, you might want to buy a put option on the S&P 500."
Just like Amazon makes suggestions of items to purchase based on what customers have viewed, Cramer would like it to also interpret linkages within the stock market and act on it.
Therefore, Cramer is officially putting a call out for Amazon to recreate the stock market. It will require horse sense, and Amazon has it. And the good news is that it won't even require delivery drones to get the job done.
One stock that actually roared higher on Friday was Red Hat, the No. 1 provider of open-sourced Linux based operating systems for enterprise, along with middleware, software for virtualization and storage.
Red Hat reported a stellar quarter on Thursday and proved it was firing on all cylinders, with a 16 percent increase in subscription business and a 14 percent rise in deferred revenue.
Cramer spoke with Red Hat's chief financial officer, Frank Calderoni, who confirmed that the company has done business with 90 percent of Fortune 500 companies.
"It's one thing to have a customer in all of the enterprise, but it's how you also sell to them and then upsell...now they are starting to see more uses on top of a Linux foundation operating system to continue to work with us," Calderoni said.
In the Lightning Round, Cramer gave his take on a few caller-favorite stocks:
Juno Therapeutics: "It's a speculative biotech in a world where even the stable biotechs are going down. So, you have to understand that stock is probably going lower in this kind of market until year end. So, act accordingly."
Calumet Specialty Products Partners: "I think that yield is unsustainable. I think you should take some off the table. I really do. I know that hurts to hear, but I think you should take some off the table."